The U.S. Food and Drug Administration has created a dedicated information page for the next phase of its generic drug user fee program, known as GDUFA IV, covering fiscal years including 2028. The agency states that information related to its preparation for the fourth reauthorization of the Generic Drug User Fee Amendments will be posted on the page as it becomes available.
While detailed proposals and timelines have not yet been published, the move marks the formal start of the public-facing process for the upcoming user fee cycle that underpins much of the FDA’s generic drug review work.
What the FDA Has Announced So Far
On its website, the FDA has posted a page titled “GDUFA IV: Fiscal Years 2028,” indicating that it will serve as the central location for materials connected to the fourth reauthorization of the Generic Drug User Fee Amendments.
In a brief notice on that page, the agency explains that information related to its preparation for GDUFA IV will be hosted there as it becomes available. The FDA does not yet list specific meeting schedules, draft commitment letters, or policy proposals on the page, and it does not provide additional narrative detail beyond identifying the page as the home for future GDUFA IV materials.
The page’s focus on fiscal years 2028 and beyond signals that the FDA is organizing its next user fee cycle around that budget period, consistent with how prior GDUFA authorizations have been structured on multi‑year timelines.
How This Fits Into the GDUFA Cycle
The Generic Drug User Fee Amendments, commonly shortened to GDUFA, are a set of authorities under which the FDA collects fees from generic drug manufacturers to support the review of their applications. Each authorization runs for a fixed number of fiscal years and must be renewed by Congress.
By labeling the new page “GDUFA IV: Fiscal Years 2028,” the FDA is indicating that this will be the fourth such authorization cycle. The agency’s notice that it will add information as it becomes available suggests that the page is intended to track the full preparation process for that cycle, from early planning through formal reauthorization steps.
The FDA’s decision to establish a dedicated page at this stage provides a single, public reference point for stakeholders who follow user fee developments. It also reflects the agency’s practice of grouping documents, announcements, and background information for each GDUFA cycle in one place.
What Is Known and What Is Not
From the information currently posted, several points are clear:
- The FDA is preparing for a fourth authorization of the Generic Drug User Fee Amendments.
- The cycle is identified with fiscal years that include 2028.
- The agency has designated a specific web page as the hub for information on GDUFA IV.
- The page will be updated over time as additional information becomes available.
At the same time, the FDA has not yet published on that page:
- A draft or final commitment letter outlining specific performance goals or policy initiatives for GDUFA IV.
- A schedule of public meetings or stakeholder consultations related to the reauthorization.
- Detailed descriptions of any proposed changes from the current user fee cycle.
The current public record therefore documents the existence and purpose of the GDUFA IV page, but leaves the substance of the upcoming reauthorization to future updates.
Independent corroboration of the GDUFA IV planning details beyond what appears on the FDA’s own website is limited at this stage. That is typical early in a user fee cycle, when the agency is still assembling materials and has not yet released draft agreements or supporting analyses.
Why the New Page Matters for Patients and Industry
Although the FDA’s GDUFA IV page is currently sparse, its creation matters because it signals the formal start of a process that affects how the agency manages generic drug reviews.
The user fee framework influences the resources available for reviewing generic applications and the performance goals the FDA sets for itself. By establishing a public hub for GDUFA IV, the agency is laying the groundwork for how those issues will be discussed and documented for the fiscal years that include 2028.
For generic drug manufacturers, the page is likely to become a key reference point for understanding upcoming expectations, timelines, and fee structures once the FDA begins posting more detailed materials. For patients and healthcare providers who follow regulatory developments, it offers a way to track the official steps the agency is taking toward the next authorization.
The FDA’s statement that information will be added as it becomes available indicates that the GDUFA IV page will evolve over time from a simple notice into a more comprehensive record of the reauthorization process.
What to Watch Next
Because the FDA has only announced the existence and purpose of the GDUFA IV page so far, the most important developments to watch will be the documents and announcements that eventually appear there.
Key milestones are likely to include the first substantive postings on the page—such as draft goals, explanatory materials, or notices of public meetings—once the agency is ready to share them. Those materials will clarify how the FDA plans to structure the next user fee cycle and how it expects that cycle to support its generic drug review work in fiscal years that include 2028.
Until then, the GDUFA IV page primarily serves as an early marker that the next phase of the generic drug user fee program is moving into view, with further details to be supplied by the FDA as its preparation progresses.
